ISB News

Scientific Wellness Meets Personalized Nutrition

Dr. Lee Hood, ISB president, and Nathan Price, ISB associate director, have joined the scientific advisory board of the newly launched Habit, which will begin to offer personalized nutrition plans based on your biology. From a recent Fast Company article:

Neil Grimmer’s new startup, called Habit, aims to help others achieve their goals, whether it’s to lose weight or sleep more soundly. The company, which is launching in January, offers a $299 blood test to screen for 60 biomarkers, including amino acids, vitamin levels, and blood sugar, as well as some genetic variants that may play a role in how an individual responds to diet. The company is also attempting to test a users’ metabolic rate through a “challenge,” which involves drinking a milkshake-like beverage to understand how they respond to fats, carbs and sugars, and then sending in another set of blood tests. Read more…

 

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.